Bristol-Myers Squibb Company stock (US0897961004): shares edge higher as investors eye valuation metrics

Bristol-Myers Squibb Company shares moved higher on the New York Stock Exchange on 06/04/2026, drawing attention to how the large US pharma group is currently valued after recent price gains and ahead of future pipeline and earnings milestones.

Bristol-Myers Squibb Company shares gained ground on the New York Stock Exchange on 06/04/2026, with the stock changing hands at around USD 56.60 during the session, according to GuruFocus as of 06/04/2026.

The move leaves the US-based pharmaceutical heavyweight in focus for investors assessing where the NYSE-listed name sits on common valuation measures after a period of share price volatility and continued execution on its drug portfolio.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia-Pacific and other international markets
• Key revenue drivers: Prescription medicines in oncology, hematology, immunology and cardiovascular disease
• Home exchange/listing venue: New York Stock Exchange (BMY)
• Trading currency: USD

Bristol-Myers Squibb Company: core business model

Bristol-Myers Squibb Company focuses on discovering, developing and commercializing branded prescription therapies across oncology, hematology, immunology and cardiovascular indications, with revenue largely generated by a portfolio of specialty medicines sold into hospitals, clinics and pharmacies worldwide.

Valuation metrics and multiples for Bristol-Myers Squibb Company

The latest price action provides a reference point for how Bristol-Myers Squibb Company screens on key valuation indicators when compared with typical ranges for large US pharmaceutical peers. On 06/04/2026 the stock was quoted at USD 56.60, a level that GuruFocus describes as around 2.3 percent above its internal GF Value estimate of USD 55.31 for the name on that date, based on GuruFocus as of 06/04/2026.

In addition to this fair-value style indicator, investors often combine the current share price with earnings and cash flow figures from the most recently reported financial year to derive common ratios such as price-to-earnings or enterprise-value-to-EBITDA for Bristol-Myers Squibb Company, using the company’s own filings alongside market data to benchmark the stock against other US and global pharmaceutical groups.

Conclusion

The latest trading session on the New York Stock Exchange, with Bristol-Myers Squibb Company shares at about USD 56.60 on 06/04/2026, highlights how investors are reassessing the US pharmaceutical group’s positioning after recent price moves.

Against this backdrop, valuation indicators such as the relationship between the share price and reference fair value estimates, as well as ratios derived from reported earnings and cash flows, remain central to how the stock is viewed within the wider US healthcare sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.